Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C.

ABSTRACT:

Aim

To evaluate and compare the efficacy and safety of telaprevir (TVR)-and simeprevir (SMV)-based triple therapies in elderly patients, specifically patients aged 66 years or older.

Methods

The present study enrolled 112 and 76 Japanese patients with chronic hepatitis C virus genotype 1b infection who were treated with a 12-wk TVR-based or SMV-based triple therapy, respectively, followed by a dual therapy that included pegylated interferon α and ribavirin (RBV) for 12 wk. The patients were categorized into two groups according to age as follows: A younger group of patients aged ≤ 65 years old and an older group of patients aged > 65 years old. Among the patients treated with TVR-based triple therapy, 34 patients were included in the older group. The median ages were 56 year

SUBMITTER: Yamagiwa S 

PROVIDER: S-EPMC5316845 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature